Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Gri Bio Inc (GRI)

Gri Bio Inc (GRI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,871
  • Shares Outstanding, K 1,914
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,210 K
  • EBIT $ -8 M
  • EBITDA $ -6 M
  • 60-Month Beta -1.67
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.19

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -83.67
  • Growth Rate Est. (year over year) +1,293.98%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3800 +9.42%
on 05/15/25
2.4300 -37.86%
on 05/02/25
unch (unch)
since 04/17/25
3-Month
1.1000 +37.27%
on 04/09/25
11.1200 -86.42%
on 04/01/25
-7.5017 (-83.24%)
since 02/19/25
52-Week
1.1000 +37.27%
on 04/09/25
106.0358 -98.58%
on 05/21/24
-91.3100 (-98.37%)
since 05/17/24

Most Recent Stories

More News
GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

GRI : 1.5200 (+1.33%)
GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025

GRI : 1.5200 (+1.33%)
GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) 

GRI : 1.5200 (+1.33%)
GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI : 1.5200 (+1.33%)
GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference

GRI : 1.5200 (+1.33%)
GRI Bio Announces Closing of $5.0 Million Public Offering

GRI : 1.5200 (+1.33%)
GRI Stock Down on Public Offering Despite Encouraging IPF Study Data

GRI Bio, Inc.’s GRI shares plummeted 36.9% on April 1 after the company announced the pricing of a public offering of stock of $5 million.Earlier in the day, the stock surged after the company reported...

FOLD : 6.28 (-2.33%)
ANIP : 59.55 (-0.73%)
GRI : 1.5200 (+1.33%)
GRI Bio Announces Pricing of $5.0 Million Public Offering

GRI : 1.5200 (+1.33%)
GRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI : 1.5200 (+1.33%)
GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan

GRI : 1.5200 (+1.33%)

Business Summary

GRI Bio Inc. is a clinical stage biopharmaceutical company which focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio Inc., formerly known as Vallon Pharmaceuticals Inc., is based in PHILADELPHIA, PA.

See More

Key Turning Points

3rd Resistance Point 1.6499
2nd Resistance Point 1.5799
1st Resistance Point 1.5400
Last Price 1.5200
1st Support Level 1.4301
2nd Support Level 1.3601
3rd Support Level 1.3202

See More

52-Week High 106.0358
Fibonacci 61.8% 65.9503
Fibonacci 50% 53.5679
Fibonacci 38.2% 41.1855
Last Price 1.5200
52-Week Low 1.1000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
OSZAR »